Therefore, given the autoimmune nature of emphysema, our human translational studies suggest that therapies that neutralize IL-17, IFN-γ, and related cytokines in ever-smokers with emphysema manifesting increased T cell responses to EFs might be similarly effective. The gene discussed is IL17A; the disease is pulmonary emphysema.